Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbohydrate biguanides as potential hypoglycemic agents.

A B Reitz1, R W Tuman, C S Marchione

  • 1Department of Chemical Research, McNeil Pharmaceutical, Spring House, Pennsylvania 19477-0776.

Journal of Medicinal Chemistry
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mephedrone ("bath salt") pharmacology: insights from invertebrates.

Neuroscience·2012
Same author

Stereochemistry and mechanism of the Wittig reaction. Diasteromeric reaction intermediates and analysis of the reaction course.

Journal of the American Chemical Society·2012
Same author

Correction. stereochemistry of the wittig reaction. Effect of nucleophillic groups in phosphonium ylide.

Journal of the American Chemical Society·2011
Same author

Recent advances in traceless linkers.

Current opinion in drug discovery & development·2009
Same author

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

British journal of cancer·2007
Same author

Benefits of a blood donation archive repository: international survey of donor repository procedures and Scottish experiences.

Transfusion·2007
Same journal

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Journal of medicinal chemistry·2026
Same journal

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Journal of medicinal chemistry·2026
Same journal

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

Journal of medicinal chemistry·2026
Same journal

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Journal of medicinal chemistry·2026
Same journal

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Journal of medicinal chemistry·2026
Same journal

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026
See all related articles

New biguanide-functionalized monosaccharides show potent hypoglycemic activity. Two compounds demonstrated efficacy comparable to established diabetes drugs phenformin and metformin.

Area of Science:

  • Carbohydrate Chemistry
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Biguanides are a class of compounds known for their hypoglycemic effects.
  • Monosaccharide derivatives offer a scaffold for developing novel drug candidates.
  • Exploring new chemical entities for diabetes management is crucial.

Purpose of the Study:

  • To synthesize and evaluate novel monosaccharide-biguanide conjugates for hypoglycemic activity.
  • To compare the efficacy of these novel compounds against existing hypoglycemic agents.

Main Methods:

  • Synthesis of various monosaccharide derivatives functionalized with biguanide groups.
  • Evaluation of hypoglycemic activity using a modified rat glucose-tolerance test.
  • Quantitative assessment of blood glucose level inhibition.

Related Experiment Videos

Main Results:

  • Compounds 8 and 23 exhibited significant hypoglycemic activity, comparable to phenformin and metformin.
  • Compound 31 showed moderate activity, with 26% inhibition of blood glucose rise.
  • Compounds 8 and 23 demonstrated potent inhibition of post-prandial hyperglycemia.

Conclusions:

  • Monosaccharide-biguanide conjugates represent a promising class of compounds for managing hyperglycemia.
  • Specific structural modifications on monosaccharides can yield potent hypoglycemic agents.
  • Further investigation into these novel biguanide derivatives is warranted for potential therapeutic applications.